Results 31 to 40 of about 3,679,356 (272)

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

The Oncologist, 2022
Background Treatment with venetoclax + hypomethylating agents (HMAs) is standard-of-care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged ≥75 years, or with comorbidities precluding intensive chemotherapy.
P. Vachhani, Evelyn M. Flahavan, T. Xu, E. Ma, M. Montez, A. Gershon, M. Onishi, Huan Jin, G. Ku, Brannon Flores, C. Bui, J. Abbas, W. Donnellan   +12 more
semanticscholar   +1 more source

TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE

Mediterranean Journal of Hematology and Infectious Diseases, 2016
Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy.
Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas   +12 more
doaj   +1 more source

DNA methylation at tobacco telomeric sequences [PDF]

, 2011
Majerová et al. (Plant Mol Biol, 2011) have recently reported that a considerable fraction of cytosines at tobacco telomeres is methylated. Although the data presented in this report indicate that tobacco telomeric sequences undergo certain levels of DNA
Vaquero Sedas, María Isabel, Vega Palas, Miguel Ángel   +1 more
core   +1 more source

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

Blood Advances, 2021
Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in ∼50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup with outcomes similar to sAML in de novo AML patients treated with intensive chemotherapy ...
Curtis A. Lachowiez, S. Loghavi, Ken Furudate, G. Montalban-Bravo, A. Maiti, T. Kadia, N. Daver, G. Borthakur, N. Pemmaraju, K. Sasaki, Y. Alvarado, M. Yilmaz, N. Short, K. Chien, M. Ohanian, S. Pierce, K. Patel, E. Jabbour, F. Ravandi, H. Kantarjian, G. Garcia-Manero, Koichi Takahashi, M. Konopleva, C. Dinardo   +23 more
semanticscholar   +1 more source

Hypomethylating agents after allogeneic blood stem cell transplantation [PDF]

Stem Cell Investigation, 2016
Allogeneic blood stem cell transplantation (allo-SCT) is a potentially curative treatment for patients with myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but relapse remains the major cause of treatment failure. So far, therapeutic options for patients with AML or MDS who relapse after allo-SCT generally
Thomas, Schroeder, Christina, Rautenberg, Rainer, Haas, Guido, Kobbe   +3 more
openaire   +2 more sources

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Acta Medica Bulgarica, 2020
Introduction: Hypomethylating agents have become a standard therapy for certain myeloid malignancies.
Varbanova V., Anastasova-Postadzhiyan A., Nedeva A., Nikolov I., Kindekov I., Kuyumdzhieva Y., Petkova N., Vikentieva E., Lubomir M., Raynov J.   +9 more
doaj   +1 more source

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

Leukemia, 2021
The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents.
C. Récher, C. Röllig, E. Bérard, S. Bertoli, P. Dumas, S. Tavitian, M. Kramer, H. Serve, M. Bornhäuser, U. Platzbecker, C. Müller-Tidow, C. Baldus, D. Martínez-Cuadrón, J. Serrano, P. Martínez-Sánchez, Eduardo-Rodriguez Arboli, C. Gil, J. Bergua, T. Bernal, A. de la Fuente Burguera, É. Delabesse, A. Bidet, A. Pigneux, P. Montesinos   +23 more
semanticscholar   +1 more source

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. [PDF]

, 2014
BackgroundIn 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of ...
A Kumari, AS Yang, C Festuccia, C Zeller, CA Stidley, CJ Piyathilake, D Ma, D Matei, D Shang, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DJ Stewart, DW Shen, E Gordian, E San Jose-Eneriz, EA Braga, F Crea, F Fang, H Iwata, H Kantarjian, H Kroeger, HM Kantarjian, J Charlet, J Shia, JA Plumb, JP Issa, JP Issa, JS Kim, K Ghoshal, K Onda, K Ramachandran, K Tikoo, KY Tse, L Ding, L Rothem, MA Kane, ML Orta, NH Nabilsi, R Zhao, RH Finnell, S Fu, S Vijayaraghavalu, SB Baylin, SS Muerkoster, T Tanaka, TB Lee, VF Chekhun, X Chang, XJ Liang, Y Li, Y Oki, Y Zhang, ZG Liu   +55 more
core   +2 more sources

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents

Journal of Hematology & Oncology, 2022
Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months.
Sangmin Lee, S. Mohan, J. Knupp, K. Chamoun, A. de Jonge, Fan Yang, E. Baloglu, J. Shah, M. Kauffman, S. Shacham, B. Bhatnagar   +10 more
semanticscholar   +1 more source